Back to Search
STEVEN KAPLAN, D.M.D.
D.M.D.
Endodontics
NPI: 1386861292Individual
Specialties, Licenses & Credentials
EndodonticsPrimary
Dentist — Endodontics
Code: 1223E0200X
034161(NY)
Research & Publications (20)
Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms.
PMID 19302502·BJU Int·2009
4-observational
PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
PMID 19328538·Urology·2009
2-rct
Enhancing the empowerment of youth in foster care: supportive services.
PMID 19653457·Child Welfare·2009
6-review
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
PMID 18510659·BJU Int·2008
4-observational
Introduction: BPH and sexual dysfunction--recommendations for the primary care physician and urologist.
PMID 19002118·Int J Impot Res·2008
8-other
Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
PMID 18639298·J Urol·2008
2-rct
Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.
PMID 18405763·J Urol·2008
8-other
Current role of alpha-blockers in the treatment of benign prostatic hyperplasia.
PMID 19032603·BJU Int·2008
6-review
Urinary retention and post-void residual urine in men: separating truth from tradition.
PMID 18485378·J Urol·2008
6-review
Prevalence of an increased ascending thoracic aorta diameter diagnosed by two-dimensional echocardiography versus 64-multislice cardiac computed tomography.
PMID 18157977·Am J Cardiol·2008
4-observational
Identification of the patient with enlarged prostate: diagnosis and guidelines for management.
PMID 17620137·Osteopath Med Prim Care·2007
8-other
[The role of muscarinic receptor antagonists in the treatment of men with lower urinary tract symptoms secondary to BPH].
PMID 17645086·Actas Urol Esp·2007
6-review
Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH.
PMID 17728048·Eur Urol·2007
6-review
Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.
PMID 17592540·Rev Urol·2007
8-other
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
PMID 17258855·Eur Urol·2007
2-rct
Prevalence of an increased ascending and descending thoracic aorta diameter diagnosed by multislice cardiac computed tomography in men versus women and in persons aged 23 to 50 years, 51 to 65 years, 66 to 80 years, and 81 to 88 years.
PMID 17996526·Am J Cardiol·2007
8-other
Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: A landmark national US survey.
PMID 16942587·Int J Clin Pract·2006
8-other
The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?
PMID 16952672·J Urol·2006
4-observational
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
PMID 17105794·JAMA·2006
4-observational
Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia.
PMID 17215996·Rev Urol·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 119 W 57TH ST, SUITE 700
NEW YORK, NY 10019 - Phone
- (212) 245-1066
Quick Facts
- NPI
- 1386861292
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile